ANCHOR CRC:恩考拉非尼联合比美替尼及西妥昔单抗一线治疗BRAFV600E突变转移性结直肠癌的单臂II期研究结果
ANCHOR CRC是一项多中心、开放标签、单臂II期研究,评估恩考拉非尼+比美替尼+西妥昔单抗一线治疗BRAFV600E突变转移性结直肠癌的疗效与安全性。95例患者局部评估确认客观缓解率为47.4%(95%CI 37.0-57.9),均為部分缓解,主要终点达成。中位随访20.1个月,中位无进展生存期5.8个月,中位总生存期18.3个月,安全性可控。
要点
- 一线恩考拉非尼+比美替尼+西妥昔单抗局部评估确认客观缓解率47.4%(95%CI 37.0-57.9),全部为部分缓解。
- 中位随访20.1个月,中位无进展生存期5.8个月,中位总生存期18.3个月。
- 安全性可控,未出现非预期毒性;第3至第10周期≥30%患者报告症状显著改善。
核心结论
- ANCHOR CRC研究显示,恩考拉非尼+比美替尼+西妥昔单抗这一科学驱动的联合方案在BRAFV600E突变转移性结直肠癌一线治疗中具有活性,安全性可控。
- 进一步的一线评估正在进行中(ClinicalTrials.gov标识符:NCT04607421)。
研究设计与样本
- 多中心、开放标签、单臂II期研究(ANCHOR CRC,ClinicalTrials.gov标识符:NCT03693170)。
- 研究纳入95例既往未治疗的BRAFV600E突变转移性结直肠癌患者。
- 治疗方案:口服恩考拉非尼300 mg每日一次,比美替尼45 mg每日两次,28天为一周期;静脉西妥昔单抗第1周期第1天400 mg/m²一次,随后前7个周期每周一次250 mg/m²,从第8周期起第1天和第15天500 mg/m²一次。
- 主要终点为局部评估的确认客观缓解率,次要终点包括中心评估的确认客观缓解率、无进展生存期、总生存期、生活质量及安全性耐受性。
主要发现
- 95例患者中,局部评估的确认客观缓解率为47.4%(95%CI 37.0-57.9),全部为部分缓解。
- 因95%CI下限超过30%,主要终点达成。
- 中位随访20.1个月,基于局部评估的中位无进展生存期为5.8个月,中位总生存期为18.3个月。
- 治疗耐受性良好,未出现非预期毒性。
- 采用患者整体印象变化量表,从第3周期至第10周期,≥30%的患者持续报告症状显著改善。
临床怎么用
- 作者认为,恩考拉非尼+比美替尼+西妥昔单抗联合方案在BRAFV600E突变转移性结直肠癌一线治疗中具有活性且安全性可控。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAFV600E-mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170). ANCHOR CRC aimed to evaluate efficacy, safety, and quality of life with first-line encorafenib + binimetinib + cetuximab in BRAFV600E-mutated mCRC. METHODS: In this multicenter, open-label, single-arm study, patients with BRAFV600E-mutated mCRC received oral encorafenib 300 mg once daily and binimetinib 45 mg twice daily in 28-day cycles, plus intravenous cetuximab 400 mg/m2 once on day 1 of cycle 1, then 250 mg/m2 once weekly for the first seven cycles, and 500 mg/m2 once on Days 1 and 15 from cycle 8 onward. The primary end point was locally assessed confirmed objective response rate (cORR), and secondary end points included centrally assessed cORR, progression-free survival, overall survival (OS), quality of life, and safety and tolerability. RESULTS: Among 95 patients, the locally assessed cORR was 47.4% (95% CI, 37.0 to 57.9) with all partial responses. Since the lower limit of the 95% CI exceeded 30%, the primary end point was met. With a median follow-up duration of 20.1 months, the median progression-free survival on the basis of local assessments was 5.8 months and the median OS was 18.3 months. Treatment was well tolerated, with no unexpected toxicities. Using Patient Global Impression of Changes, substantial improvement in symptoms was consistently reported in ≥ 30% of patients from cycle 3 to cycle 10. CONCLUSION: The ANCHOR CRC study showed that the scientifically driven combination of encorafenib + binimetinib + cetuximab was active in the first-line setting of BRAFV600E-mutated mCRC with a manageable safety profile. Further first-line evaluation is ongoing (ClinicalTrails.gov identifier: NCT04607421).
引用
- Van Cutsem E, Taieb J, Yaeger R, et al. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. J Clin Oncol. 2023. PMID: 36763936. doi:10.1200/JCO.22.01693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。